Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
8.05
+0.01 (0.12%)
At close: Apr 1, 2025, 4:00 PM
8.07
+0.02 (0.21%)
After-hours: Apr 1, 2025, 4:55 PM EDT
Aurinia Pharmaceuticals Revenue
In the year 2024, Aurinia Pharmaceuticals had annual revenue of $235.13M with 33.97% growth. Aurinia Pharmaceuticals had revenue of $59.87M in the quarter ending December 31, 2024, with 32.76% growth.
Revenue (ttm)
$235.13M
Revenue Growth
+33.97%
P/S Ratio
4.89
Revenue / Employee
$1,808,715
Employees
130
Market Cap
1.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AUPH News
- 4 weeks ago - Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga
- 4 weeks ago - Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - Business Wire
- 5 weeks ago - Aurinia Pharmaceuticals: There's Still Time For Sales Growth - Seeking Alpha
- 5 weeks ago - Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Business Wire
- 2 months ago - 3 Biotech Stocks With Notable Insider Buying - Seeking Alpha
- 4 months ago - Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
- 4 months ago - Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - Business Wire